Terms: = Breast cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2
832 results:
1. The pRb/RBL2-E2F1/4-GCN5 axis regulates cancer stem cell formation and G0 phase entry/exit by paracrine mechanisms.
Chang CH; Liu F; Militi S; Hester S; Nibhani R; Deng S; Dunford J; Rendek A; Soonawalla Z; Fischer R; Oppermann U; Pauklin S
Nat Commun; 2024 Apr; 15(1):3580. PubMed ID: 38678032
[TBL] [Abstract] [Full Text] [Related]
2. Decoding the Versatile Landscape of Autophagic Protein VMP1 in cancer: A Comprehensive Review across Tissue Types and Regulatory Mechanisms.
Renna FJ; Gonzalez CD; Vaccaro MI
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612567
[TBL] [Abstract] [Full Text] [Related]
3. A glycolytic metabolite bypasses "two-hit" tumor suppression by BRCA2.
Kong LR; Gupta K; Wu AJ; Perera D; Ivanyi-Nagy R; Ahmed SM; Tan TZ; Tan SL; Fuddin A; Sundaramoorthy E; Goh GS; Wong RTX; Costa ASH; Oddy C; Wong H; Patro CPK; Kho YS; Huang XZ; Choo J; Shehata M; Lee SC; Goh BC; Frezza C; Pitt JJ; Venkitaraman AR
Cell; 2024 Apr; 187(9):2269-2287.e16. PubMed ID: 38608703
[TBL] [Abstract] [Full Text] [Related]
4. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
5. Withaferin A alters the expression of microRNAs 146a-5p and 34a-5p and associated hub genes in MDA-MB-231 cells.
Shuaib M; Chaudhri S; Kumar S
Biomol Concepts; 2024 Jan; 15(1):. PubMed ID: 38525814
[TBL] [Abstract] [Full Text] [Related]
6. Detection of Single Nucleotide Polymorphisms of Circulating Tumor DNA by Strand Displacement Amplification Coupled with Liquid Chromatography.
Ma Z; Xu J; Hou W; Lei Z; Li T; Shen W; Yu H; Liu C; Zhang J; Tang S
Anal Chem; 2024 Apr; 96(13):5195-5204. PubMed ID: 38520334
[TBL] [Abstract] [Full Text] [Related]
7. Nuclear localization of heparanase 2 (Hpa2) attenuates breast carcinoma growth and metastasis.
Hilwi M; Shulman K; Naroditsky I; Feld S; Gross-Cohen M; Boyango I; Soboh S; Vornicova O; Farhoud M; Singh P; Bar-Sela G; Goldberg H; Götte M; Sharrocks AD; Li Y; Sanderson RD; Ilan N; Vlodavsky I
Cell Death Dis; 2024 Mar; 15(3):232. PubMed ID: 38519456
[TBL] [Abstract] [Full Text] [Related]
8. Impact of kras mutation on the tumor microenvironment in colorectal cancer.
Zhou Y; Kuang Y; Wang C; Yu Y; Pan L; Hu X
Int J Biol Sci; 2024; 20(5):1947-1964. PubMed ID: 38481800
[TBL] [Abstract] [Full Text] [Related]
9. Emerging role of tumor suppressing microRNAs as therapeutics in managing non-small cell lung cancer.
Singh S; Saxena S; Sharma H; Paudel KR; Chakraborty A; MacLoughlin R; Oliver BG; Gupta G; Negi P; Singh SK; Dua K
Pathol Res Pract; 2024 Apr; 256():155222. PubMed ID: 38452582
[TBL] [Abstract] [Full Text] [Related]
10. Detailed DNA methylation characterisation of phyllodes tumours identifies a signature of malignancy and distinguishes phyllodes from metaplastic breast carcinoma.
Meyer B; Stirzaker C; Ramkomuth S; Harvey K; Chan B; Lee CS; Karim R; Deng N; Avery-Kiejda KA; Scott RJ; Lakhani S; Fox S; Robbins E; Shin JS; Beith J; Gill A; Sioson L; Chan C; Krishnaswamy M; Cooper C; Warrier S; Mak C; Rasko JE; Bailey CG; Swarbrick A; Clark SJ; O'Toole S; Pidsley R
J Pathol; 2024 Apr; 262(4):480-494. PubMed ID: 38300122
[TBL] [Abstract] [Full Text] [Related]
11. Liprin-α1 contributes to oncogenic MAPK signaling by counteracting ERK activity.
Pehkonen H; Filippou A; Väänänen J; Lindfors I; Vänttinen M; Ianevski P; Mäkelä A; Munne P; Klefström J; Toppila-Salmi S; Grénman R; Hagström J; Mäkitie AA; Karhemo PR; Monni O
Mol Oncol; 2024 Mar; 18(3):662-676. PubMed ID: 38264964
[TBL] [Abstract] [Full Text] [Related]
12. Blockade of CD93 in pleural mesothelial cells fuels anti-lung tumor immune responses.
Zhang C; Nan X; Zhang B; Wu H; Zeng X; Song Z; Li S; Wang J; Xie S; Zhang G; Xiu H; Wang J; Guo J; Wang P; Cai Z; Zhen Y; Shen Y
Theranostics; 2024; 14(3):1010-1028. PubMed ID: 38250037
[No Abstract] [Full Text] [Related]
13. Mutant kras-activated circATXN7 fosters tumor immunoescape by sensitizing tumor-specific T cells to activation-induced cell death.
Zhou C; Li W; Liang Z; Wu X; Cheng S; Peng J; Zeng K; Li W; Lan P; Yang X; Xiong L; Zeng Z; Zheng X; Huang L; Fan W; Liu Z; Xing Y; Kang L; Liu H
Nat Commun; 2024 Jan; 15(1):499. PubMed ID: 38216551
[TBL] [Abstract] [Full Text] [Related]
14. HDAC inhibitors target IRS4 to enhance anti‑AR therapy in AR‑positive triple‑negative breast cancer.
He Y; Ma Y; Zhu Y; Zhang J; Zhao S; Zhang D; Xu D; Li Y; Tong Z; Zhao W
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38214343
[TBL] [Abstract] [Full Text] [Related]
15. The dual activity of CaONPs as a cancer treatment substance and at the same time resistance to harmful microbes.
Awaad A; Olama ZA; El-Subruiti GM; Ali SM
Sci Rep; 2023 Dec; 13(1):22940. PubMed ID: 38135693
[TBL] [Abstract] [Full Text] [Related]
16. Integrative analysis of transcriptomic and metabolomic profiles reveals enhanced arginine metabolism in androgen-independent prostate cancer cells.
Dai X; Shi X; Luo M; Li P; Gao Y
BMC Cancer; 2023 Dec; 23(1):1241. PubMed ID: 38104097
[TBL] [Abstract] [Full Text] [Related]
17. Functional pri-miR-34b/c rs4938723 and kras 3'UTR rs61764370 SNPs: Novel phenotype modifiers in Li-Fraumeni Syndrome?
Vieira IA; Pezzi EH; Bandeira IC; Reis LB; de Araújo Rocha YM; Fernandes BV; Siebert M; Miyamoto KN; Siqueira MB; Achatz MI; Galvão HCR; Garcia FAO; Campacci N; Carraro DM; Formiga MN; Vianna FSL; Palmero EI; Macedo GS; Ashton-Prolla P
Gene; 2024 Mar; 898():148069. PubMed ID: 38070788
[TBL] [Abstract] [Full Text] [Related]
18. Mucinous cystadenocarcinoma of the breast harbours TRPS1 expressions and PIK3CA alterations.
Chen WY; Hu YH; Tsai YH; Hang JF; Tan PH; Chen CJ
Histopathology; 2024 Feb; 84(3):550-555. PubMed ID: 37983855
[TBL] [Abstract] [Full Text] [Related]
19. Individual participant data from digital sources informed and improved precision in the evaluation of predictive biomarkers in Bayesian network meta-analysis.
Umemneku-Chikere CM; Wheaton L; Poad H; Ray D; Andrade IC; Khan S; Tappenden P; Abrams KR; Owen RK; Bujkiewicz S
J Clin Epidemiol; 2023 Dec; 164():96-103. PubMed ID: 37918640
[TBL] [Abstract] [Full Text] [Related]
20. An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic cancer Guides Rational Therapies.
Hasselluhn MC; Schlösser D; Versemann L; Schmidt GE; Ulisse M; Oschwald J; Zhang Z; Hamdan F; Xiao H; Kopp W; Spitalieri J; Kellner C; Schneider C; Reutlinger K; Nagarajan S; Steuber B; Sastra SA; Palermo CF; Appelhans J; Bohnenberger H; Todorovic J; Kostyuchek I; Ströbel P; Bockelmann A; König A; Ammer-Herrmenau C; Schmidleitner L; Kaulfuß S; Wollnik B; Hahn SA; Neesse A; Singh SK; Bastians H; Reichert M; Sax U; Olive KP; Johnsen SA; Schneider G; Ellenrieder V; Hessmann E
Gastroenterology; 2024 Feb; 166(2):298-312.e14. PubMed ID: 37913894
[TBL] [Abstract] [Full Text] [Related]
[Next]
